BACK TO ISCBH HOME

Getting to Montreal

GET IN TOUCH
By Air

Montreal is served by Montréal–Trudeau International Airport (YUL), located approximately 20 km (12 miles) from downtown.
• Taxi: A fixed fare of approximately CAD $45 applies to downtown Montreal.
• Bus: The 747 Express Bus runs 24/7 between the airport and downtown (approx. 45–60 minutes, CAD $11, includes unlimited STM public transport for 24 hours).
• Private transfers and rideshares such as Uber are also widely available.

 

By Train

Montreal’s Gare Centrale (Central Station) is the main rail hub for VIA Rail and Amtrak services, with regular connections from Toronto, Ottawa, Quebec City, and New York. The station is about a 10-minute walk or short metro ride from Centre Mont-Royal.

 

By Car

Montreal is easily accessible by highway:
• From Toronto: Highway 401 East → Autoroute 20 East
• From Quebec City: Autoroute 20 West
Public parking is available near the venue and at nearby hotels, though delegates are encouraged to use public transport.

 

Travel Documents

International delegates may require a visa or Electronic Travel Authorization (eTA) to enter Canada. Please check your specific requirements early via the official Government of Canada website: www.cic.gc.ca/visit

 
Visa

Please check your passport and visa requirements before travelling.
Citizens of many countries — including the UK, USA, EU nations, Australia, New Zealand, and Japan — can visit Canada visa-free for up to six months. However, most travellers arriving by air must obtain an Electronic Travel Authorization (eTA) in advance.
For full and up-to-date entry information, visit the Government of Canada’s official travel website: https://www.cic.gc.ca

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

WEBSITE

At Kyowa Kirin, patients are at the center of everything we do. We are a global specialty pharmaceutical company dedicated to discovering and advancing innovative medicines for rare and hard-to-treat diseases where unmet need is greatest. Based in Japan with worldwide operations, we work across the continuum—from drug discovery to commercialization—guided by our commitment to patients and their families. Backed by more than 70 years of life sciences leadership, we focus on bone and mineral disorders, hemato-oncology, and rare diseases. Rooted in collaboration, we accelerate development through partnerships with industry, academia, patients, and healthcare providers. Learn more: KyowaKirin.com

WEBSITE

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

WEBSITE
BridgeBio Logo

At BridgeBio, our mission is to turn beautiful science into meaningful medicines for the people who need it most. BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations.

WEBSITE

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

WEBSITE

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

WEBSITE